Research on Long-acting Glaucoma Treatment Published in Advanced Materials

January 6, 2025

Research completed by Synakis’ Mickael Dang, Molly Shoichet, and co-authors on a long-acting treatment for glaucoma has been published in Advanced Materials! Dang et al. developed the treatment by embedding drug-rich nanoparticles called colloidal drug aggregates (CDA) into Synakis’ ocular biomaterial to enable long-acting controlled release of timolol - a beta-blocker used to lower intraocular pressure (IOP) in glaucoma patients. Non-invasive administration of the treatment into the subconjunctival space of rat eyes enabled a prolonged IOP-lowering effect for 7 weeks! This research is the basis of Synakis’ pipeline product SNK-225 for the treatment of glaucoma.